IP Library Granted Patent US 12,351,798
Granted Patent B1
US 12,351,798 · App. 18/328,320 · Granted Jul 8, 2025

Methods for depletion of high-copy sequences in multiplexed whole genome sequencing libraries

Inventors: David Lee (San Francisco, CA); Justin Lock (San Francisco, CA)
Assignee: COLOR HEALTH, INC.
C12N15/1065C12N15/1093C12Q1/6806
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,351,798
App. No.
18/328,320
Granted
Jul 8, 2025
Kind
B1
Abstract

A depleted sequencing library can be prepared by providing a composition comprising a heterogeneous mixture of linear nucleic acids having a first terminus and a second terminus. A first subset of target nucleic acids and a second subset of non-target nucleic acids can include a first adaptor region at the first terminus and a second adaptor region at the second terminus. A third subset of the target nucleic acids and a fourth subset of the non-target nucleic acids include the second adaptor region at the first terminus and at the second terminus. Removable blocker oligonucleotides can be added to the composition, non-target nucleic acids can be removed from the composition by sequence capture to bait oligonucleotides, and the composition can be treated to reduce a quantity of free blocker oligonucleotides that are not annealed to an adaptor sequence or to a sequence substantially complementary to an adaptor sequence.

Claims (30)

1. A method for preparing a depleted sequencing library comprising:

a) providing a composition comprising a heterogeneous mixture of linear nucleic acids having a first terminus and a second terminus, wherein the heterogeneous mixture comprises a plurality of target nucleic acids and a plurality of non-target nucleic acids, wherein;

a first subset of the plurality of target nucleic acids and a second subset of the plurality of non-target nucleic acids comprise an at least partially double-stranded first adaptor region at the first terminus and an at least partially double-stranded second adaptor region at the second terminus,

the first adaptor region comprises a first adaptor sequence and a sequence at least partially complementary to the first adaptor sequence,

the second adaptor region comprises a second adaptor sequence and a sequence at least partially complementary to the second adaptor sequence, and

a third subset of the plurality of target nucleic acids and a fourth subset of the plurality of non-target nucleic acids comprise the at least partially double-stranded second adaptor region at the first terminus and the at least partially double-stranded second adaptor region at the second terminus;

b) adding removable blocker oligonucleotides to the composition, wherein the removable blocker oligonucleotides comprise:

(i) first removable blocker oligonucleotides that anneals to the first adaptor sequence, and

(ii) second removable blocker oligonucleotides that anneals to the second adaptor sequence,

wherein:

 at least a portion of the removable blocker oligonucleotides are RNA oligonucleotides, and

at least one of the removable blocker oligonucleotides selected from the removable blocker oligonucleotides in (i) and (ii) is added in excess over the first adaptor sequence and the second adaptor sequence to which it hybridizes so that a quantity of the at least one of the removable blocker oligonucleotides is not annealed to an adaptor sequence and is free in solution;

c) removing non-target nucleic acids from the composition by sequence capture to bait oligonucleotides thereby depleting the non-target nucleic acids from the composition; and

d) treating the composition by a combination of heat of at least 70° C., addition of divalent ions, and a pH greater than 7 to reduce the quantity of free blocker oligonucleotides that are not annealed to the adaptor sequence or to a sequence substantially complementary to the adaptor sequence, whereby the composition comprises the depleted sequencing library.

2. The method of claim 1 , wherein Step (d) comprises treating the composition to reduce the quantity of the first removable blocker oligonucleotides that are annealed to first adaptor sequences and/or a quantity of the second removable blocker oligonucleotides are annealed to second adaptor sequences.

3. The method of claim 2 , wherein the blocker oligonucleotides that are annealed and the blocker oligonucleotides that are not annealed are removed at same time under same conditions.

4. The method of claim 1 , further comprising

e) obtaining the plurality of target nucleic acids from the depleted sequencing library; and

f) sequencing at least a portion of the plurality of target nucleic acids.

5. The method of claim 1 , wherein the removable blocker oligonucleotides are further degraded by an enzyme.

6. The method of claim 5 , wherein the enzyme is an RNase.

7. The method of claim 1 , wherein at least another portion of the removable blocker oligonucleotides are DNA oligonucleotides.

8. The method of claim 7 , wherein the DNA oligonucleotides comprise uracil.

9. The method of claim 8 , wherein the DNA oligonucleotides can be degraded by an uracil-DNA-glycosylase.

10. The method of claim 1 , wherein the removable blocker oligonucleotides are from 40 to 80 nucleotides in length.

11. The method of claim 1 , wherein the non-target nucleic acids are high-copy nucleic acid sequences, transposable elements, tandem repeats, highly transcribed genes, high-copy contaminating DNAs, and/or CRISPR repeats.

12. The method of claim 1 , wherein the composition comprises the linear nucleic acids isolated from multiple samples.

13. The method of claim 12 , wherein the nucleic acids from each sample are labeled with a sample-specific barcode sequence.

14. The method of claim 1 , wherein the bait oligonucleotides comprise an affinity label that enables subsequent capture of the non-target nucleic acids.

15. The method of claim 14 , wherein the affinity label is a biotin group.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2023
From: LEE, DAVID; LOCK, JUSTIN
To: COLOR HEALTH, INC.
Reel/Frame 064524/0023 →
Continuity (2)
Continuation 17332610 · May 27, 2021
Provisional Application 63032006 · May 29, 2020
References Cited (10)
US 20060257902A1 · Mendoza et al. · 2006 [cited by applicant]
US 20110091939A1 · Cui · 2011 [cited by applicant]
US 20130261027A1 · Li et al. · 2013 [cited by applicant]
US 20140243232A1 · Meredith · 2014 [cited by examiner]
US 20150119261A1 · Richard · 2015 [cited by applicant]
US 20170159040A1 · Lock et al. · 2017 [cited by applicant]
US 20180291436A1 · Wang et al. · 2018 [cited by applicant]
WO WO2016055956A1 · 2016 [cited by examiner]
WO 2020036991A1 · 2020 [cited by applicant]
WO 2022248237A1 · 2022 [cited by applicant]